Skip to main content

Serum tetranectin is an independent prognostic marker in colorectal cancer and weakly correlated with plasma suPAR, plasma PAI-1 and serum CEA

Buy Article:

$51.00 plus tax (Refund Policy)

Abstract:

Høgdall CK, Christensen IJ, Stephens RW, Sørensen S, Nørgaard-Pedersen B, Nielsen HJ. Serum tetranectin is an independent prognostic marker in colorectal cancer and weakly correlated with plasma suPAR, plasma PAI-1 and serum CEA. APMIS 2002;110:630–8.

Soluble tetranectin (TN) was measured preoperatively in serum from 567 patients with primary colorectal cancer and levels were tested for association with prognosis. The prognostic significance of TN was also compared to that of plasminogen-activator inhibitor-1 (PAI-1), urokinase plasminogen activator (uPAR) and carcinoembryonic antigen (CEA). Significantly shorter survival was found for patients with TN levels below a cut-off point of 7.5 mg/l compared to patients with levels above, as illustrated by Kaplan-Meier curves. By Cox analyses, log TN, log soluble uPAR as well as log CEA were found to have an independent prognostic value for survival (log TN: HR=0.47, 95% CI: 0.29–0.76); log soluble uPAR: HR=1.65, 95% CI: 1.18–2.31; log CEA: HR=1.11, 95% CI: 1.03–1.20). Based on the multivariate model, a patient with a combination of low levels of TN and PAI-1 and elevated levels of soluble uPAR and CEA had a 2.43 increased risk as compared to a patient with median levels of these biochemical markers. Significant correlations were found with Dukes' stages for all the biochemical markers and between the respective biochemical markers. The findings confirm that TN is a strong prognostic factor in patients with colorectal cancer. TN may be valuable as a prognostic variable in future studies evaluating new treatment strategies for colorectal cancer.

Keywords: PAI-1; Tumor markers; colorectal cancer; prognostic factors; suPAR; tetranectin

Document Type: Research Article

DOI: https://doi.org/10.1034/j.1600-0463.2002.1100906.x

Affiliations: 1: Finsen Laboratory, Rigshospitalet, Copenhagen, 2: Department of Clinical Biochemistry, Hvidovre Hospital, University of Copenhagen, 3: Department of Clinical Biochemistry, Statens Serum Institut, Copenhagen,

Publication date: 2002-09-01

  • Access Key
  • Free ContentFree content
  • Partial Free ContentPartial Free content
  • New ContentNew content
  • Open Access ContentOpen access content
  • Partial Open Access ContentPartial Open access content
  • Subscribed ContentSubscribed content
  • Partial Subscribed ContentPartial Subscribed content
  • Free Trial ContentFree trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more